Business
Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds
TOKYO, February 25, 2026--Asahi Kasei Pharma announced an exclusive global license agreement regarding novel lead compounds for a single target with Alchemedicine.
About this update from Asahi Kasei Corporation
[{"type":"image","alt":"Asahi Kasei's Tokyo Headquarters","displaySize":"","headline":null,"caption":"Asahi Kasei's Tokyo Headquarters","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":320,"url":"https://media.zenfs.com/en/business-wire.com/66fd01f5c38735e82b39e9127f805b58"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/075GzJO8Z.i.LOIcu4pmVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/66fd01f5c38735e82b39e9127f805b58","width":480,"height":320}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4999,"height":683,"url":"https://media.zenfs.com/en/business-wire.com/92ee006bf15d40e8d3b53ec630c730ac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rsWYXDuGhxySMreCo0lxhg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/92ee006bf15d40e8d3b53ec630c730ac","width":960,"height":131},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/JLZKLefSE6whtb3i2ljXxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMjg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/92ee006bf15d40e8d3b53ec630c730ac","width":1200,"height":164}}},{"type":"text","content":"TOKYO, February 25, 2026--(BUSINESS WIRE)--Asahi Kasei Pharma announced that it has strengthened its drug discovery pipeline through an exclusive global license agreement regarding novel lead compounds for a single target with Alchemedicine, a company specializing in the discovery of small molecule drugs. The license agreement was executed on February 3, 2026, and follows the companies’ recent announcement on advancing AK1960 to a Phase I study.","length":449,"tagName":"p"},{"type":"text","content":"Under the agreement, Asahi Kasei Pharma obtained exclusive worldwide rights to research, develop, manufacture, and commercialize the compounds, which are currently at the preclinical stage. The compounds were identified using Alchemedicine’s drug discovery platform, HiSAP™1 and are expected to have therapeutic potential for multiple autoimmune diseases. The specific target indications will be determined by Asahi Kasei Pharma as development progresses.","length":455,"tagName":"p"},{"type":"text","content":"This agreement represents the second license agre...